🎥✨ Martes de Divulgación Científica - 14 de octubre 2025 - Atrofia muscular espinal

Value of the Information & Strength of the Argument

The value of the information is high, as it provides original data on diagnostic delays for SMA in Peru, a topic with limited published data. The study’s methodology is sound for a cross-sectional design, using a structured survey and including both hospital and association patients. The argumentation is logical, starting with disease background, then presenting the study’s objectives, methods, results, and conclusions. The speaker effectively uses comparative data from other countries to contextualize the findings. However, the study’s reliance on self-reported data may introduce recall bias, and the sample size is relatively small. The speaker also acknowledges limitations such as the lack of genetic confirmation for some patients and the potential underdiagnosis of type 1. Overall, the argumentation is persuasive and clinically relevant.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is good: the study is clearly described, with data analysis using SPSS, and the speaker cites historical references (Werdnig, Hoffman, Kugelberg, Welander, Melki) for the disease’s discovery and genetic basis. The title accurately reflects the content, which is a scientific dissemination session. The sources are not explicitly cited in the video, but the speaker mentions the availability of genetic testing at the Instituto de Salud del Niño de Breña and the patient association. The adequacy between title and content is excellent. No comments were provided, so no analysis of public trends is included.

The title accurately reflects the content: a scientific dissemination session on spinal muscular atrophy, focusing on diagnostic age in Peru.

8/10

The presentation is based on a cross-sectional study with clear methodology, data from 51 patients, and comparisons with international data. The speaker is a neurologist with relevant credentials. Limitations include potential selection bias and reliance on self-reported data, but the study is transparent and clinically relevant.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction of the speaker and topic.
• 02:00Explanation of SMA genetics and pathophysiology.
• 05:00Description of SMA types 1-4 and their clinical features.
• 10:00Presentation of the study objectives and methodology.
• 15:00Results: median ages of symptom onset and diagnosis for each type.
• 20:00Analysis of first consultation and referral patterns, highlighting delays.
• 25:00Comparison with international data from Italy and Argentina.
• 30:00Conclusions and recommendations for early diagnosis.
• 33:20Q&A session on red flags in primary care.

• Instituto de Salud del Niño de Breña — Mentioned as the center where genetic testing for SMA is available in Peru.
• Asociación de Pacientes con AME Perú — Collaborated in the study by providing access to patients.

• Diagnostic delay in spinal muscular atrophy: a systematic review — The study's findings align with global evidence of diagnostic delays in SMA.

• Potential underdiagnosis of SMA type 1 — The study suggests that type 1 SMA may be underdiagnosed, as some patients may die from respiratory complications without a confirmed diagnosis.